retatrutide weight loss clinical trials retatrutide The drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering Retatrutide, an investigational triple hormone
Description
Until retatrutide has equivalent data, semaglutide is the evidence-based choice for people with established heart disease
This is in addition to the hypophagic effects of endogenous GLP1 via peripheral GLP1 receptors (Ruttimann et al., 2009)
Ivanievi et al
The New England Journal of Medicine commentary accompanying SURPASS-2 stated: "The dual incretin approach appears to exploit receptor crosstalk in ways that amplify downstream insulin secretion beyond what GLP-1 receptor agonism alone can achieve at comparable tolerability." [30] SURPASS-1: Monotherapy Benchmark SURPASS-1 (N=478) established monotherapy efficacy, with tirzepatide 15 mg reducing A1C by 2.07 percentage points and body weight by 9.5 kg at 40 weeks versus placebo [31]

By one year, more than 40% of participants had lost at least 20% of their body weight

In both cases, these medications are intended to be used long-term in combination with lifestyle interventions to support overall wellbeing
